Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis

INDIANAPOLIS, Sept. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE : LLY ) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz® (ixekizumab)... Biopharmaceuticals Eli Lilly, Taltz, ixekizumabd, Tremfya, guselkumab, psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news